Background: Breast cancer (BC) remains a leading cause of cancer-related mortality among women worldwide. Metastasis to lymph nodes is a critical determinant of prognosis and treatment decisions. MicroRNAs (miRNAs), small non-coding RNA molecules, have emerged as promising biomarkers due to their regulatory roles in gene expression.Aim of the study: This review evaluates the current understanding and potential applications of miRNAs as biomarkers for lymph node metastasis in BC patients.Material and methods: A comprehensive literature search was conducted using the PubMed and Google Scholar databases. Studies published between 2005 and 2023 were included, focusing on research articles, clinical trials, and reviews addressing miRNAs in the context of lymph node metastasis in BC. Keywords included "miRNA," "breast cancer," and "lymph node metastasis." Relevant articles were selected based on relevance, methodological rigor, and their contribution to the field.Results: Current research highlights the pivotal role of miRNAs in the metastatic process of breast cancer. Key miRNAs, such as miR-124, miR-10b, and miR-155, contribute to either promoting or inhibiting metastasis by influencing pathways involved in cell proliferation, migration, and invasion. For instance, miR-124 suppresses multiple steps of metastasis by targeting pro-metastatic genes, while miR-10b regulates genes associated with cell motility. Clinical studies indicate that the expression profiles of multiple miRNAs can serve as predictive biomarkers for lymph node metastasis, offering insights into tumor aggressiveness and potential therapeutic targets in BC.Conclusions: The identification of miRNAs as biomarkers for lymph node metastasis in BC holds significant promise for improving diagnostic accuracy and advancing personalized treatment strategies. Despite these advancements, further research is needed to validate current findings in larger and more diverse patient populations, and to standardize detection methods. A deeper understanding of the molecular mechanisms underlying miRNA regulation will enhance their clinical applicability. Ultimately, integrating miRNA profiling into clinical practice could revolutionize BC management, leading to improved prognostic tools for early detection and more effective targeted therapies.